Inclusion Criteria:

- Histoloically confirmed prostate adenocarcinoma within 365 days of registration.

- Clinical stages T1a-T2c N0 M0 (AJCC Criteria 6th Ed). For any pelvic lymph node > 1.5
cm, biopsy of the lymph node is mandatory.

- Histological evaluation of prostate biopsy with assignment of a Gleason score to the
biopsy material; Gleason score must be in the range 2-7. Biopsy with >6 cores is
strongly recommended. (The highest Gleason Score in any core reported on the
pathology report will be used for determining inclusion.)

- PSA values < 20ng/ml within 90 days prior to registration, and done either prior to
prostate biopsy, or at least 21 days after prostate biopsy. If Gleason score is < 6,
PSA value should be < 10 ng/ml.

- Zubrod status 0-1 documented within 60 days of registration.

- Androgen deprivation is at the discretion of the treating radiation oncologist.

- Patients must give IRB approved study specific informed consent.

- Patients must complete all required tests (History/Physical exam, Zubrod performance
status, CBC, PSA, CT or MRI, Transrectal ultrasound with prostate core
biopsies/Histological evaluation, Transrectal prostate fiducial marker placement,
Bone scan, Bone x-ray or CT (if bone scan is equivocal), EPIC, EQ-5D, IPSS QOL
instruments, Kilovoltage images, x-rays, fluoroscopy, 4D CT-scan, Prostate
ultrasound, MRI diffusion, Calypso localization and tracking, Directed prostate
biopsy, Local Pathology review, Physics consultation, Follow-Up Phone Call)

- Patients must be able to start treatment within 56 days of registration.

- Patients must be at least 18 years old.

- Members of all races and ethnic groups are eligible for this trial.